TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01272622

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)

Intervention type: OTHER
Group type: OTHER
Intervention: wait and watch
Description: wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
Study: NCT05509673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipofilling (sublesional fat grafting)
Study: NCT04287647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpyloric stent
Description: See arm/group descriptions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study: NCT00153920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT02719860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: 4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black tea
Description: 4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
Study: NCT01067911

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
Study: NCT01889563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Training Program Exercise
Description: Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
Study: NCT02244528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study: NCT02440399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Please see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Please see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study: NCT04663620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Saving Babies Lives Programme
Description: Comprehensive neonatal healthcare package

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Saving Babies Lives Programme
Description: No comprehensive neonatal healthcare package
Study: NCT01912040

Intervention type: DRUG
Intervention: Administration of 123Iodine MIBG
Description: Patients will be administered the locally produced 123 Iodine MIBG
Study: NCT02758379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Lithoplasty System
Description: Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
Study: NCT01908738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracervical block with 1%lidocaine
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracervical block with 1%lidocaine
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
Study: NCT02440399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)
Study: NCT01301001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 2 capsules am and 3 capsules pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo 2 capsules am and 3 capsules pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg am and 1800 mg pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 1200 mg am and 1800 mg pm
Study: NCT00862901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIPT patch
Description: A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
Study: NCT01908738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10%lidocaine spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10%lidocaine spray
Study: NCT01445054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium CHX-A
Description: 111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
Study: NCT03137576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block (PVB)
Description: PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Description: ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
Study: NCT01683500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave therapy with Modulith SLK (Storz)
Description: Three sessions with shock wave therapy, interval of one week.
Study: NCT00862901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIPT patch
Description: A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIPT patch
Description: A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLIPT patch
Description: A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
Study: NCT02202720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Short term sedation with sevoflurane in ICU
Study: NCT04520451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: oral tablet or capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: oral tablet or capsule
Study: NCT01557816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Naproxen
Description: Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for seven days given BID during either of the 2 treatment periods.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo for seven days given BID during either of the 2 treatment periods.
Study: NCT01856660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat Diet
Description: Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
Study: NCT01216280

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: 2 x 10 mg placebo capsules administered orally with water, b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Natura-alpha capsule and 10 mg placebo capsule
Description: 10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 10 mg Natura-alpha capsules
Description: 2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
Study: NCT06251830

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI exam with Magnetic Resonance Fingerprinting
Description: Acquisition of MRI data with technique Magnetic Resonance Fingerprinting
Study: NCT00887081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
Description: PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
Study: NCT00728416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study: NCT04901897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A
Description: kalifilcon A daily disposable contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
Study: NCT00656461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: 30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
Study: NCT01095705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure
Description: Local anaesthesia (Lidocaïne)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional procedure + Hypnosis
Description: Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
Study: NCT02717013

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing calcium lactate similar to the HMB capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing calcium lactate similar to the HMB capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB
Description: HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB
Description: HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
Study: NCT03393299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria
Description: software which helps to do the drug reconciliation
Study: NCT03701100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS
Study: NCT04901897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
Study: NCT03063073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Study: NCT00939263

Intervention type: OTHER
Intervention: assessment of disease activity using the EEsAI
Description: disease activity index

Intervention type: OTHER
Intervention: assessment of disease activity using the EEsAI
Description: disease activity index
Study: NCT03613428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dose escalation up to 80 mg administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 i.v. weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg orally 5 consecutive days per week for 4 weeks.
Study: NCT03230201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Description: Lymph node dissection during radical nephroureterectomy
Study: NCT02764021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Restricted Diet
Description: Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antidiabetic Diet
Description: Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
Study: NCT04665882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary surgery based on lymphedema prediction nomogram
Description: Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
Study: NCT01153464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Support Counseling
Description: Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
Study: NCT04172129

Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Study: NCT03123185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet and solution formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet and solution formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Test)
Description: Fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564 (Reference)
Description: Fasting state
Study: NCT03243188

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
Study: NCT02491450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heterosofir
Description: 1 tablet contains 400 mg sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaldi
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT04129801

Intervention type: OTHER
Intervention: Isokinetic Dynamometer
Description: Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.

Intervention type: OTHER
Intervention: Bioimpedance
Description: Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
Study: NCT02116062

Intervention type: DEVICE
Group type: OTHER
Intervention: 1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)

Intervention type: DEVICE
Group type: OTHER
Intervention: Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)

Intervention type: DEVICE
Group type: OTHER
Intervention: Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot
Study: NCT02313272

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Irradiation (HFSRT)
Description: Radiation therapy treatment (FSRT) which will be given to participants over 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.